LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician
Journal of Cardiac Failure · 2023
DOI: 10.1016/j.cardfail.2023.08.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiac Failure, 2023. Verfasst von Karen Flores Rosario und 7 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, North Carolina. Hauptthemen laut MEDLINE: Heart Failure, Cardiomyopathies, Cardiomyopathy, Dilated. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: A diagnosis of Lamin proteins A and C cardiomyopathy (LMNA-CM) not only impacts disease prognosis, but also leads to specific guideline-recommended treatment options for these patients. This etiology is fundamentally different from other genetic causes of dilated CM. METHODS AND RESULTS: LMNA-CM often presents early in the third to fourth decades and there is an age-dependent penetrance of nearly 90% among those with a positive genotype for LMNA-CM. Oftentimes, electrical abnormalities with either conduction disturbances and/or either atrial or ventricular arrhythmias manifest before there is imaging evidence of left ventricular dysfunction. Given these subtle early findings, cardiac magnetic resonance provides helpful guidance regarding patterns of enhancement associated with LMNA-CM, often before there is significant left ventricular dilation and/or a decrease in the ejection fraction and could be used for further understanding of risk stratification and prognosis of asymptomatic genotype-positive individuals. Among symptomatic patients with LMNA-CM, approximately one-quarter of individuals progress to needing advanced heart failure therapies such as heart transplantation. CONCLUSIONS: In the era of precision medicine, increased recognition of clinical findings associated with LMNA-CM and increased detection by genetic testing among patients with idiopathic nonischemic CM is of increasing importance. Not only does a diagnosis of LMNA-CM have implications for management and risk stratification, but new gene-based therapies continue to be evaluated for this group. Clinicians must be aware not only of the general indications for genetic testing in arrhythmogenic and dilated cardiomyopathies and of when to suspect LMNA-CM, but also of the clinical trials underway targeted toward the different genetic cardiomyopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Medical Center, Durham, North Carolina.
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Duke University School of Medicine, Durham, North Carolina.
- Duke University Medical Center, Durham, North Carolina. Electronic address: kpf9@duke.edu.
Zitieren
APA
Rosario, K. F., Karra, R., Amos, K., Landstrom, A. P., Lakdawala, N. K., Brezitski, K., Kim, H., & Devore, A. D. (2023). LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2023.08.016
Vancouver
Rosario KF, Karra R, Amos K, Landstrom AP, Lakdawala NK, Brezitski K, et al. LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician. Journal of Cardiac Failure. 2023. doi:10.1016/j.cardfail.2023.08.016
BibTeX
@article{Rosario2023,
author = {Rosario, Karen Flores and Karra, Ravi and Amos, Kaitlyn and Landstrom, Andrew P and Lakdawala, Neal K and Brezitski, Kyla and Kim, Han and Devore, Adam D},
title = {LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician},
journal = {Journal of Cardiac Failure},
year = {2023},
doi = {10.1016/j.cardfail.2023.08.016}
}
EUVIMED